Payment overview · 2025
General Payments
$547.88
28 reported records · 7 companies
Healthcare provider profile · identity verified
Hang Zhu
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BROOKLYN, NY · NPI 1669846242
Verified facts
What the public records show
CMS Open Payments records show Hang Zhu received $547.88 in general payments during 2025 across 28 reported records.
Esperion Therapeutics, Inc. accounted for 58.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Nexletol.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexlizet by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $317.59 | 58.0% | 15 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $95.87 | 17.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.09 | 10.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.26 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.17 | 3.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.33 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.57 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $547.88 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $317.59 | 15 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $95.87 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.09 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 62 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 68 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
62 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1463 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1084 | 137 |
| Alendronate Sodium | Alendronate Sodium | 787 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 690 | 83 |
| Losartan Potassium | Losartan Potassium | 599 | 77 |
| Finasteride | Finasteride | 524 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 523 | 67 |
| Metformin Hcl | Metformin Hcl | 434 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 416 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 395 | 45 |
| Simvastatin | Simvastatin | 370 | 44 |
| Januvia | Sitagliptin Phosphate | 254 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 215 | 76 |
| Diclofenac Sodium | Diclofenac Sodium | 177 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 23 |
| Omeprazole | Omeprazole | 172 | 83 |
| Ammonium Lactate | Ammonium Lactate | 151 | 45 |
| Gabapentin | Gabapentin | 137 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 80 |
| Meclizine Hcl | Meclizine Hcl | 127 | 74 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 122 | 25 |
| Fenofibrate | Fenofibrate,micronized | 122 | 18 |
| Glipizide | Glipizide | 121 | 14 |
| Trazodone Hcl | Trazodone Hcl | 116 | 53 |
| Jardiance | Empagliflozin | 112 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 109 | 19 |
| Atenolol | Atenolol | 108 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 107 | 43 |
| Montelukast Sodium | Montelukast Sodium | 106 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 95 | 28 |
| Halobetasol Propionate | Halobetasol Propionate | 90 | 64 |
| Allopurinol | Allopurinol | 79 | 11 |
| Diclofenac Epolamine | Diclofenac Epolamine | 78 | 35 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 71 | 18 |
| Linzess | Linaclotide | 68 | 11 |
| Procto-Med Hc | Hydrocortisone | 68 | 24 |
| Lisinopril | Lisinopril | 63 | suppressed |
| Creon | Lipase/Protease/Amylase | 62 | 24 |
| Acarbose | Acarbose | 59 | suppressed |
| Loperamide | Loperamide Hcl | 57 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 33 |
| Clotrimazole | Clotrimazole | 49 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | suppressed |
| Ursodiol | Ursodiol | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Meloxicam | Meloxicam | 44 | 34 |
| Ketoconazole | Ketoconazole | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 30 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 18 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 23 |
| Mometasone Furoate | Mometasone Furoate | 34 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Repaglinide | Repaglinide | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 18 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Nexletol | Bempedoic Acid | 31 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 27 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 14 |
| Jentadueto | Linagliptin/Metformin Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Colchicine | Colchicine | 17 | 11 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $547.88 · 28 records | Esperion Therapeutics, Inc. | CREON, LINZESS, NEXLETOL, OTEZLA, REPATHA, REZDIFFRA, XIFAXAN, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error